- Home
- TBBK vs ZLAB Comparison
TBBK vs ZLAB Comparison
Compare TBBK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBBK
- ZLAB
- Stock Information
- Founded
- TBBK 1999
- ZLAB 2013
- Country
- TBBK United States
- ZLAB China
- Employees
- TBBK N/A
- ZLAB N/A
- Industry
- TBBK Major Banks
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- TBBK Finance
- ZLAB Health Care
- Exchange
- TBBK Nasdaq
- ZLAB Nasdaq
- Market Cap
- TBBK 2.4B
- ZLAB 3.6B
- IPO Year
- TBBK 2004
- ZLAB 2017
- Fundamental
- Price
- TBBK $58.90
- ZLAB $36.40
- Analyst Decision
- TBBK Buy
- ZLAB Buy
- Analyst Count
- TBBK 3
- ZLAB 5
- Target Price
- TBBK $65.33
- ZLAB $54.28
- AVG Volume (30 Days)
- TBBK 498.6K
- ZLAB 886.6K
- Earning Date
- TBBK 07-24-2025
- ZLAB 08-05-2025
- Dividend Yield
- TBBK N/A
- ZLAB N/A
- EPS Growth
- TBBK 20.50
- ZLAB N/A
- EPS
- TBBK 4.42
- ZLAB N/A
- Revenue
- TBBK $502,282,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- TBBK N/A
- ZLAB $44.07
- Revenue Next Year
- TBBK $6.71
- ZLAB $49.13
- P/E Ratio
- TBBK $13.33
- ZLAB N/A
- Revenue Growth
- TBBK 10.02
- ZLAB 43.72
- 52 Week Low
- TBBK $37.65
- ZLAB $16.01
- 52 Week High
- TBBK $65.84
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- TBBK 71.00
- ZLAB 52.67
- Support Level
- TBBK $55.58
- ZLAB $34.79
- Resistance Level
- TBBK $51.43
- ZLAB $36.73
- Average True Range (ATR)
- TBBK 1.67
- ZLAB 1.23
- MACD
- TBBK 0.65
- ZLAB -0.46
- Stochastic Oscillator
- TBBK 91.55
- ZLAB 25.91
About TBBK The Bancorp Inc
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.